Recent advances in retinopathy of prematurity

International Ophthalmology Clinics

Volumn 41, Issue 4, 2001, Pages 129-151

  Nguyen, Q D ^a   Tawansy, K ^a   Hirose, T ^a  

^a RETINA FOUNDATION OF THE SOUTHWEST   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SURFACTANT;

ARTICLE; BLINDNESS; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DISEASE SEVERITY; HUMAN; INTENSIVE CARE; LASER COAGULATION; NEWBORN; OXYGEN THERAPY; PRIORITY JOURNAL; RACE; RESPIRATORY DISTRESS SYNDROME; RETROLENTAL FIBROPLASIA; VITRECTOMY;

COST-BENEFIT ANALYSIS; HUMANS; INFANT, NEWBORN; RETINOPATHY OF PREMATURITY; RISK FACTORS;

EID: 0034773561     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200110000-00013     Document Type: Article

References (98)

1. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: I. Preliminary report
2. Intensive oxygen therapy as a possible cause for retrolental fibroplasia. A clinical approach
3. Causes of cerebral palsy
4. Retinopathy of prematurity: Diagnosis, severity, and natural history
5. An international classification of retinopathy of prematurity: II. The classification of retinal detachment
6. An international classification of retinopathy of prematurity
7. Retinopathy of prematurity
8. Incidence and early course of retinopathy of prematurity
9. Retinopathy of prematurity: Incidence and severity in Hawaii
10. Retinopathy of prematurity and associated factors
11. Correlation of retinopathy of prematurity in fellow eyes in the cryotherapy for retinopathy of prematurity study
12. Retinopathy of prematurity: An estimate of vision loss in the United States - 1979
13. Advanced cicatricial retinopathy of prematurity - Outcome and complications
14. Retinopathy of prematurity: The continuing threat to vision in preterm infants. Dutch survey from 1986 to 1994
15. The decreasing incidence and severity of retinopathy of prematurity
16. Current incidence of retinopathy of prematurity, 1989-1997
17. Incidence and characteristics of retinopathy of prematurity in a low-income inner-city population
18. Retinopathy of prematurity: Lack of association with prenatal care
19. Racial variation in retinopathy of prematurity
20. Retinal traction in vitro. Biophysical aspects
21. Retinal traction in vivo and postmortem
22. Experimental retinal detachment. Biophysical aspects of retinal peeling and stretching
23. Retinopathy of prematurity: Risk factors in a prospective population-based study
24. 2
25. Vitamin E and retrolental fibroplasia in 1982
26. Problems on retinopathy of prematurity: Statistical analysis of factors related to occurrence and progression of retinopathy and fundus appearance and ocular functions in prematurely born subjects
27. Blood transfusions: Possible potentiating risk factor in retrolental fibroplasia
28. Effect of bright light in the hospital nursery on the incidence of retinopathy of prematurity
29. Controlled trial of D-penicillamine to prevent retinopathy of prematurity
30. Oxygen toxicity: Membrane damage by free radicals
31. The biology of oxygen radicals
32. Autooxidative damage to the retina: Potential role in retinopathy of prematurity
33. Supplemental oxygen therapy: Basis for noninvasive treatment of retinopathy of prematurity
34. Causes
35. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial: I. Primary outcomes
36. Supplemental oxygen may decrease progression of prethreshold disease to threshold retinopathy of prematurity
37. Oxygen therapy in acute retinopathy of prematurity stage 3
38. What can we learn from STOP-ROP and earlier studies?
39. 2 modulation of intraretinal oxygen levels in an avascular retina
40. Lack of efficacy of light reduction in preventing retinopathy of prematurity
41. Oxygen therapy, oxygen toxicity, and the STOP-ROP trial
42. Serial phospholipid analysis in preterm infants: Comparison of Exosurf and Survanta
43. Overview of clinical trials comparing natural and synthetic surfactants
44. Natural vs synthetic surfactants in neonatal respiratory distress syndrome
45. Synthetic or natural surfactants
46. Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity
47. Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: A multicentre prospective randomized trial
48. Double-blind developmental evaluation at 1-year corrected age of 597 premature infants with birth weights from 500 to 1350 grams enrolled in three placebo-controlled trials of prophylactic synthetic surfactant
49. Surfactant treatment in the neonate with severe respiratory distress syndrome
50. Calf lung surfactant extract prophylaxis and retinopathy of prematurity
51. Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity
52. Retinopathy of prematurity in surfactant treated infants
53. Surfactant prophylaxis and retinopathy of prematurity
54. Randomized clinical trial of surfactant prophylaxis in retinopathy of prematurity
55. Bovine surfactant therapy and retinopathy of prematurity
56. Retinopathy of prematurity and surfactant treatment
57. Screening for retinopathy of prematurity after surfactant treatment
58. Less severe retinopathy of prematurity induced by surfactant replacement therapy
59. Retinopathy of prematurity in a controlled trial of prophylactic surfactant treatment
60. One-year follow-up of 89 infants with birthweights of 500-749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo
61. Retinopathy of prematurity in infants less than 29 weeks' gestation: 31/2 Years pre- and post-surfactant
62. Health and neurodevelopmental outcome at 1-year adjusted age in 508 infants weighing 700 to 1100 grams who received prophylaxis with one versus three doses of synthetic surfactant
63. One-year follow-up evaluation of 260 premature infants with respiratory distress syndrome and birth weights of 700 to 1350 grams randomized to two rescue doses of synthetic surfactant or air placebo
64. Double-blind evaluation of developmental and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo
65. One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo
66. One-year follow-up of 66 premature infants weighing 500 to 699 grams treated with a single dose of synthetic surfactant or air placebo at birth: Results of a double-blind trial
67. One-year outcome in 232 premature infants with birth weights of 750 to 1249 grams and respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air placebo
68. Severe retinopathy of prematurity in extremely low birth weight infants after short-term dexamethasone therapy
69. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: A randomized, controlled trial
70. Early (4-7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants
71. Bilirubin levels and severe retinopathy of prematurity in infants with estimated gestational ages of 23 to 26 weeks
72. Dopamine use is an indicator for the development of threshold retinopathy of prematurity
73. Glutathione status in retinopathy of prematurity
74. Surgical advances in retinopathy of prematurity
75. Multicenter trial of cryotherapy for retinopathy of prematurity: Preliminary results
76. Multicenter trial of cryotherapy for retinopathy of prematurity: Three-month outcome
77. Multicenter trial of cryotherapy for retinopathy of prematurity: One-year outcome - Structure and function
78. Multicenter trial of cryotherapy for retinopathy of prematurity: 31/2 Year outcome - Structure and function
79. Multicenter trial of cryotherapy for retinopathy of prematurity: Snellen visual acuity and structural outcome at 51/2 years after randomization
80. The natural ocular outcome of premature birth and retinopathy
81. Laser photocoagulation for stage 3+ retinopathy of prematurity
82. Comparison of photocoagulation with the argon, krypton, and diode laser indirect ophthalmoscopes in rabbit eyes
83. Diode laser photocoagulation for zone I threshold retinopathy of prematurity
84. Threshold retinopathy of prematurity. Transition from cryopexy to laser treatment
85. Transcleral vs transpupillary diode laser photocoagulation for the treatment of threshold retinopathy of prematurity
86. Angle-closure glaucoma after laser treatment for retinopathy of prematurity
87. Scleral buckling for retinopathy of prematurity
88. Open-sky vitrectomy in severe retinal detachment caused by advanced retinopathy of prematurity
89. Development of vision in retinopathy of prematurity
90. Vision in stage 5 retinopathy of prematurity after retinal reattachment by open-sky vitrectomy
91. Stage 5 retinopathy of prematurity
92. The role of ultrasound in the management of retinopathy of prematurity
93. Echographic findings in infants with ROP
94. An ultrasonographic study of stage-5 retinopathy of prematurity
95. Axial length biometry in infants with retinopathy of prematurity
96. The incidence of ophthalmologic interventions in children with birth weights less than 1251 grams. Results through 51/2 years
97. Cost-effectiveness of treatment for threshold retinopathy of prematurity
98. Retinopathy of prematurity in middle-income countries